SEC Form 4 · accession 0001209191-17-047496
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pascale Witz
Director
Period of report
Aug 2, 2017
Accepted (ET)
Aug 3, 2017 · 6:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $12.19 | Aug 2, 2017 | A | 52,232 | A | — | Aug 1, 2027 | Ordinary shares | 52,232 | 52,232 | D |
| Restricted Stock UnitsF2,F3 | — | Aug 2, 2017 | A | 24,610 | A | — | — | Ordinary shares | 24,610 | 24,610 | D |
Explanation of responses
- F1The option vests in 36 equal monthly installments from the date of grant.
- F2Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- F3The shares subject to the restricted stock units shall vest in three equal annual installments, beginning on the first anniversary of the grant date.